(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
ALLOGENE THERAPEUTICS, INC. | |||||||||||
By: | /s/ David Chang, M.D., Ph.D. | ||||||||||
David Chang, M.D., Ph.D. | |||||||||||
President, Chief Executive Officer |
Cover |
Mar. 10, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Mar. 10, 2023 |
Entity Registrant Name | Allogene Therapeutics, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-38693 |
Entity Tax Identification Number | 82-3562771 |
Entity Address, Address Line One | 210 East Grand Avenue |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | 650 |
Local Phone Number | 457-2700 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | ALLO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001737287 |
Amendment Flag | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
M
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
I XS-3%,9;3*0GC!'??UQ?5=;E4 M!O4<$TY[R2@B-3)C0X8"=U8[#1&,WL:\\0QXD"CL#R**5_(Y)4GT>='[^KRN MON1E!.0%J#2JX\5:(E5D)+ N2V+4,6E$D'Q 1R?B%N>-1]C#FEGT!Y''ZVG= ML3BZ2>^X!M_;+1UXIUT@*C"&HC:!6,\4R92.2D618AS7S?P6;9@ )MS.?#5U M.PYY]Y*C.%]7Y4/YE%&1M'&4I&"Q>'8H5^\L(X)2'H*-POIL5-B?(@X+_82[ MF*,HW''X/]5YVT)Y4FTV5^5]B=0L750 9N7JU\PP:ES7RP9.AN9301]0"VC]\0K8XGE M8 &GL2BH'B6%YYC#=##A'N5(&G RW\<>)HH)]RFW1.NTQ'':-%=0/_)%Q> B MUC[<6D^DX G+9AD)[J@HD\Z22-N4R#,+A@EEPHW+K5*\ZP4%XA4NBK>,AXN\ M+;!25BDJ&3+"?&>[5XK82"51,2KG#%69D^.6DR>(P^0PX5;E* IW'/Z+VG=? MJ7V\W80*UT N,F$3)9IA#B29UL0Y&P@W!J2RCE,WKK)X!# O(D\ M]&]OXMJ7*^A?Y6.FJRT/@O#8K7&> _?]$NHP#4RXZSB: MRDET&]]NH%ZAE/]35]?M&A>W2U_>+E7 Z0H$$&L,UD646^*"X4A1U)@.26GY M-CZ3>1%\V(=3D^\WCB=V$OHX0 UJ+^9O&,O#,\<+1W?Z+[Z3Z#/]K[ M/U!+ 0(4 Q0 ( !& :E8[ZHIM[1( .9W 1 " 0 M !A;&QO+3(P,C,P,S$P+FAT;5!+ 0(4 Q0 ( !& :E;F_H]-9P( &(' M 1 " 1P3 !A;&QO+3(P,C,P,S$P+GAS9%!+ 0(4 Q0 M ( !& :E9DD !X=PH $1> 5 " ;(5 !A;&QO+3(P M,C,P,S$P7VQA8BYX;6Q02P$"% ,4 " 1@&I6/N':.J4& #4, %0 M @ %<( 86QL;RTR,#(S,#,Q,%]P &UL4$L%!@ $ - 0 ! $ #0G $! end